
Spravato® is an FDA-approved breakthrough treatment for treatment resistant major depressive disorder (TRD) in adults. It is an intranasal medicine, prescribed along with an oral antidepressant.
Clinical trials have shown over 60% response rate, and 52% remission rate in patients treated with Spravato® with minimal side effects.

Who can benefit from Spravato®?
Spravato® is FDA-approved to treat two specific types of depression in adults:
- Treatment-Resistant Depression (TRD)
Treatment-resistant depression is depression that does not improve with two or more antidepressants tried at adequate dosages and duration. - Major Depressive Disorder with Suicidal Ideations
If you have major depressive disorder and have expressed suicidal thoughts or behaviors, Spravato® nasal spray may be an appropriate next step in treatment.

Spravato
50% - 70%
Response rate
62%
better social functioning
53%
better quality of life
Source:
https://www.janssenscience.com